Sales momentum accelerated in Q3 19 driven by the robust performance in the vaccines segment, particularly the shingles drug. The pharma (led by respiratory and immunology franchise) and consumer healthcare segments also performed well. The solid top-line was enough to absorb the higher R&D and SG&A expenses, and was further helped by lower tax and finance costs to facilitate the second EPS guidance upgrade for the year.
04 Nov 2019
Solid Q3 results in second EPS guidance upgrade for the year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid Q3 results in second EPS guidance upgrade for the year
GSK plc (GSK:LON) | 1,638 -245.8 (-0.9%) | Mkt Cap: 67,914m
- Published:
04 Nov 2019 -
Author:
Rishabh Kochar -
Pages:
3
Sales momentum accelerated in Q3 19 driven by the robust performance in the vaccines segment, particularly the shingles drug. The pharma (led by respiratory and immunology franchise) and consumer healthcare segments also performed well. The solid top-line was enough to absorb the higher R&D and SG&A expenses, and was further helped by lower tax and finance costs to facilitate the second EPS guidance upgrade for the year.